Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant

Kale, Hrishikesh; Qureshi, Zaina P.; Shah, Ruchit; Khandker, Rezaul Karim; Botteman, Marc; Meng, Weilin; Benca, Ruth M.

doi:10.1007/s12325-021-01891-8

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Daley et al (2009) 151 estimated the cost of insomnia in Quebec to be about $6.6 billion (Can), and the largest proportion of expenses were related to indirect costs (for example, work absences and decreased productivity). Many believe that insomnia treatment would greatly curtail such costs, but at present only a few studies demonstrate that this is the case 152 – 155 . Assuming that treatment does result in substantial health-care cost savings, the widespread implementation of insomnia treatment remains beyond reach.…”

Section: “Now What (What’s Next)?”mentioning

confidence: 99%

We know CBT-I works, now what?

Muench¹,

Vargas²,

Grandner³

et al. 2022

Fac Rev

View full text Add to dashboard Cite

Cognitive behavioral therapy for insomnia (CBT-I) has been shown to be efficacious and now is considered the first-line treatment for insomnia for both uncomplicated insomnia and insomnia that occurs comorbidly with other chronic disorders (comorbid insomnia). The purposes of this review are to provide a comprehensive summary of the efficacy data (for example, efficacy overall and by clinical and demographic considerations and by CBT-I formulation) and to discuss the future of CBT-I (for example, what next steps should be taken in terms of research, dissemination, implementation, and practice).

show abstract

Section: “Now What (What’s Next)?”mentioning

confidence: 99%

We know CBT-I works, now what?

Muench¹,

Vargas²,

Grandner³

et al. 2022

Fac Rev

View full text Add to dashboard Cite

show abstract

Suvorexant initiation reduces resource use and costs for insomnia patients in the USA

2021

PharmacoEcon Outcomes News

View full text Add to dashboard Cite

The initiation of suvorexant [Belsomra; Merck] treatment appears to result in immediate and continued decreases in healthcare resource use (HCRU) and costs in insomnia patients in the USA, according to the results of a study funded by Merck, Sharp and Dohme.The researchers conducted a retrospective cohort study that used de-identified medical and pharmacy claims data from the US nationwide Optum Clinformatics Data Mart claims database of adults diagnosed with insomnia between 1 January 2010 and 31 December 2018 newly initiated on suvorexant (prevalent and incident insomnia were examined separately). The outcomes of interest were changes in all-cause HCRU and associated direct medical and nonmedical costs * (calculated at monthly intervals) from 12 months before to 12 months after suvorexant initiation.In total, the study included 18,919 patients with prevalent insomnia and 5939 patients with incident insomnia. For the prevalent insomnia group, the mean age was 64.5 years, 65% were female, 74% had Medicare coverage, and 61% had a Charleson comorbidity score of C1; these parameters were similar for the incident group. The trend for monthly total healthcare cost was increasing prior to suvorexant initiation ($US52.51 and $74.93 in the prevalent and incident groups, respectively); however, after suvorexant initiation, the monthly total costs showed a decreasing trend in both cohorts. The decrease in total healthcare costs after suvorexant initiation was equivalent to $72.66 and $112.07 per month in each group, respectively. The monthly trends in HCRU rates also decreased. The decreases were 1.5-3 times greater for patients with mental health comorbidities.

show abstract